HDAC inhibition induces microRNA-182 which targets Rad51 and impairs HR repair to sensitize cells to sapacitabine in acute myelogenous leukemia

Por Lai, Tsung-Huei, Ewald, Brett, Zecevic, Alma, Liu, Chaomei, Sulda, Melanie, Papaioannou, Dimitrios, Garzon, Ramiro, Blachly, J.S, Plunkett, William, Sampath, Deepa
Publicado no Clin Cancer Res (2016)

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia

Por Eisfeld, A-K, Mrózek, K, Kohlschmidt, J, Nicolet, D, Orwick, S, Walker, C J, Kroll, K W, Blachly, J S, Carroll, A J, Kolitz, J E, Powell, B L, Wang, E S, Stone, R M, de la Chapelle, A, Byrd, J C, Bloomfield, C D
Publicado no Leukemia (2017)

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Por Woyach, J.A., Ruppert, A.S., Heerema, N.A., Zhao, W., Booth, A.M., Ding, W., Bartlett, N.L., Brander, D.M., Barr, P.M., Rogers, K.A., Parikh, S.A., Coutre, S., Hurria, A., Brown, J.R., Lozanski, G., Blachly, J.S., Ozer, H.G., Major-Elechi, B., Fruth, B., Nattam, S., Larson, R.A., Erba, H., Litzow, M., Owen, C., Kuzma, C., Abramson, J.S., Little, R.F., Smith, S.E., Stone, R.M., Mandrekar, S.J., Byrd, J.C.
Publicado no N Engl J Med (2018)